Business
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
- Q-Code assigned to CIMERLI® for Medicare claims processing effective for dates of service on and after April 1, 2023 - - COHERUS Solutions™ patient services
About this update from Coherus Oncology, Inc.
[{"type":"text","content":"- Q-Code assigned to CIMERLI® for Medicare claims processing effective for dates of service on and after April 1, 2023 - - COHERUS Solutions™ patient services hub is available to facilitate successful access and reimbursement - REDWOOD CITY, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that the Centers for Medicare and Medicaid Services (CMS) has published a new code pursuant to the Company’s application for Healthcare Common Procedure Coding System (HCPCS) Q-codes. The HCPCS Q-code assigned to CIMERLI® will be effective for patients administered CIMERLI® on or after April 1, 2023. Paul Reider, Chief Commercial Officer of Coherus, said, \"This is an important milestone in the CIMERLI® launch. Beginning April 1st, use of CIMERLI’s permanent, product-specific Q-code will enable more efficient billing processes and speed time to reimbursement for providers. We believe that Q-code utilization will serve as a catalyst for market conversion, accelerating growth in 2023 starting in the second quarter. We want to thank CMS for its consideration and timely review of our Q-code application.” CIMERLI® is the first and only FDA-approved biosimilar interchangeable with Lucentis® (ranibizumab injection) for all indications including neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV). CIMERLI® is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab products or any of the excipients in CIMERLI®. Hypersensitivity reactions may manifest as severe intraocular inflammation.1 Coherus Solutions™ offers healthcare professionals comprehensive practice and patient support that includes extensive patient assistance, industry-leading electronic services, and office support to ensure successful access and reimbursement. About Q-Codes Q-codes are permanent reimbursement codes granted to biosimilars and used by commercial insurance plans, Medicare, Medicare Advantage, and other government payers for Medicare Part B drugs like CIMERLI® that are administered by a physician. Claims submission and documentation are simplified with a permanent Q-code, facilitating and streamlining the ...